¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"transport chain"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • sympathetic chain
    (¢¡sympathetic trunk) ±³°¨½Å°æÁÙ±â
  • gamma chain disease
    °¨¸¶°í¸®º´
  • heavy-chain disease
    Áß°í¸®º´
  • nuclear chain fiber
    Çٻ罽¼¶À¯, Çٻ罽±ÙÀ°¼¼Æ÷
  • open chain form
    ¿­¸°»ç½½Çü
  • side chain isomerism
    ¿·»ç½½À̼º
  • light-chain nephropathy
    °¡º­¿î»ç½½ÄáÆÏº´Áõ
  • straight chain molecule
    °ðÀº»ç½½ºÐÀÚ
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ, ÁßÇÕ¿¬¼â¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • alpha (¥á) chain disease
    ¾ËÆÄ»ç½½º´, ¾ËÆÄ¼âº´
  • alpha chain disease
    ¾ËÆÄ¼âº´(¡­áðÜ»).
  • alpha chain disease
    ¾ËÆÄ¼âÁúȯ
  • alpha-chain disease
    ¾ËÆÄ¼â Áúȯ(¡­áð òðü´)
  • atomic chain
    ¿øÀÚ¼â(ê«í­áð).
  • beta (¥â) chain
    º£Å¸»ç½½, º£Å¸¼â
  • branched chain amino acid
    ºÐÁö¼â¾Æ¹Ì³ë»ê
  • chain
    »ç½½, ¼â
  • chain
    ¿¬¼â(ææáð), ¼â(áð), °í¸®, »ç½½.
  • chain combination
    ¿¬¼â°áÇÕ.
  • chain compound
    »ç½½È­ÇÕ¹°.
  • chain cystourethrography
    °í¸® ¹æ±¤¿äµµ Á¶¿µ¼ú
  • chain fiber
    ¿¬¼â¼¶À¯(ææáðàéë«)
  • chain index
    ¿¬¼âÁö¼ö.
  • chain initiation reaction
    ¿¬¼â°³½Ã¹ÝÀÀ (¡­ËÒã·Úãëë).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • chain-growth polymer
    »ç½½½ÅÀå(ãßíþ)ÁßÇÕü(ñìùêô÷)
  • chain initiation
    »ç½½Çü¼º(û¡à÷)°³½Ã(ËÒã·)
  • chain isomer
    »ç½½À̼ºÃ¼(ì¶àõô÷)
  • chain length
    »ç½½ ±æÀÌ
  • chain propagation
    »ç½½ Áõ½Ä(ñòãÖ)
  • chain reaction
    ¿¬¼â¹ÝÀÀ(ææáðÚãëë)
  • chain termination
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ)
  • chain termination codon
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ) ÄÚµç
  • chain termination mutation
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ) º¯ÀÌ(ܨì¶)
  • chain terminator
    »ç½½Çü¼º(û¡à÷) Á¾·áÀÚ(ðûÖõí­)
  • chain terminator method
    »ç½½Çü¼º(û¡à÷) Á¾·áÀÚ¹ý(ðûÖõí­Ûö)
  • closed chain
    "´ÝÈù »ç½½, Æó¼â(øÍáð) (ÔÒ) ring"
  • decay chain
    "ºØ±«(ÝÚÎÕ) »ç½½, (ÔÒ) radioactive series"
  • delta chain
    µ¨Å¸ »ç½½
  • DNA polymerase chain reaction
    DNA Æú¸®¸Ó·¹À̽º ¿¬¼â ¹ÝÀÀ(ææáðÚãëë) (ÔÒ) polymerase chain reaction
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HAChT high affinity choline transport
HTL hamster tumor line; hearing threshold level; high-L-leucine transport; histotechnologist; human T-ce...
HTR histidine transport regulator; 5-hydroxytryptamine receptor
IVOTTS Irvine viable organ-tissue transport system
LEUT leucine transport
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
4F2HC 4F2 heavy chain
AS-PCR Allele specific polymerase chain reaction
AP-PCR Arbitrarily primed Polymerase Chain Reaction
AP PCR Arbitrary primed polymerase chain reaction
BCAA Branched Chain Amino Acid
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
facilitated transport The protein-mediated transport of a compound across a biomembrane that is not ion-driven; a saturable transport system.
Synonym: passive transport.
(05 Mar 2000)
A chain A polypeptide component of insulin containing 21 amino acyl residues, beginning with a glycyl residue (NH2-terminus); insulin is formed by the linkage of an A chain to a B chain by two disulfide bonds; the amino-acid composition of the A chain is a function of species.
Synonym: glycyl chain.
In general, one of the polypeptides in a multiprotein complex.
(05 Mar 2000)
alpha chain disease A vague or indefinite term; could be used for alpha-heavy-chain disease (a lymphoplasma cell proliferative disease usually seen in Mediterranean men, characterised by intestinal involvement with steatorrhoea, often progressive with fatal outcome) or a thalassaemia (a genetic abnormality in the alpha globin chain of haemoglobin).
(05 Mar 2000)
amino acids, branched-chain Amino acids which have a branched carbon chain.
(12 Dec 1998)
B chain A polypeptide component of insulin containing 30 amino acyl residues, beginning with a phenylalanyl residue (NH2-terminus); insulin is formed by the linkage of a B chain to an A chain by two disulfide bonds; the amino-acid composition of the B chain is a function of species.
Synonym: phenylalanyl chain.
(05 Mar 2000)
behaviour chain Related behaviours in a series in which each response serves as a stimulus for the next response.
(05 Mar 2000)
branched chain acyl-CoA oxidase <enzyme> Enzyme from human liver peroxisomes acts on both 2-methyl branched fatty acyl- and bile acid-CoA intermediates, unlike rat liver peroxisomes which have separate enzymes for branched chain fatty acids (pristanoyl-CoA) and bile acid-CoA; involved in beta-oxidation of fatty acids and bil
Registry number: EC 1.3.3.-
Synonym: 2-methyl-branched chain acyl-CoA oxidase, hbrcacox
(26 Jun 1999)
branched-chain fatty-acid-kinase <enzyme> From anaerobic spirochete ma-2
Registry number: EC 2.7.2.14
Synonym: isovalerate kinase, 2-methylbutyrate kinase, isobutyrate kinase
(26 Jun 1999)
branched-chain fatty acid synthetase <enzyme> Analogous to fatty acid synthetase complex but starting with a branched chain keto acid; from bacillis subtilis
Registry number: EC 2.3.1.-
Synonym: bcfa synthetase
(26 Jun 1999)
branched chain ketoaciduria Hereditary disease due to deficiency of an enzyme involved in amino acid metabolism, characterised by urine that smells like maple syrup.
(12 Dec 1998)
branched chain ketonuria Hereditary disease due to deficiency of an enzyme involved in amino acid metabolism, characterised by urine that smells like maple syrup.
(12 Dec 1998)
gene rearrangement, alpha-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, beta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, heavy chain Ordered rearrangement of b-lymphocyte variable gene regions thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, light chain Ordered rearrangement of b-lymphocyte variable gene regions coding for the kappa or lambda light chains, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cold chain
    Àú¿Â À¯Åë ü°è(»ý¼±.¾ßäµîÀ» ³ÃÀå,Àú¿Â »óÅ·Π°ø±ÞÇÔ)
  • daisy chain
    µ¥ÀÌÁö ȭȯ;ÁÙÁÙÀÌ À̾îÁø °Í;(»ç°Ç,Ç׸ñ,´Ü°è µîÀÇ)¿¬¼â
  • door chain
    µµ¾ð üÀÎ(¹æ¹ü¿ë ¹®ÀÇ ¼è»ç½½)
  • drag chain
    (±â)¹ÙÄû ¸ØÃß´Â ¼è»ç½½;(Â÷·®ÀÇ)¿¬°á »ç½½;(ºñÀ¯)Àå¾Ö¹°;¹æÇع°
  • fission chain reaction
    Çٺп­ ¿¬¼â ¹ÝÀÀ
  • fob chain
    ½Ã°èÁÙ(²ö,¸®º»)
  • food chain 1
    ¸ÔÀÌ¿¬¼â;½Ä·áǰ ¿¬¼âÁ¡
  • guard chain
    (½Ã°è µûÀ§ÀÇ)»ç½½ÁÙ
  • heavy chain
    (¸é¿ª ±Û·ÎºÒ¸°ÀÇ)Áß¿¬¼â
  • light chain
    Àü±â ½ºÅĵåÀÇ ²ö
  • mountain chain
    »ê¸Æ
  • watch chain
    ȸÁß ½Ã°èÀÇ ¼èÁÙ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á